Literature DB >> 11306790

Bacterial adhesiveness: effects of the SH metabolite of erdosteine (mucoactive drug) plus clarithromycin versus clarithromycin alone.

P C Braga1, T Zuccotti, M Dal Sasso.   

Abstract

After metabolization, erdosteine (a mucoactive drug) produces an active metabolite (Met I) with an SH group that is capable of opening disulphide bonds, including those of pilin, a protein of bacterial fimbriae. This induces stereochemical conformational changes that interfere with the binding of bacterial adhesins (fimbriae) to receptors on eukaryotic cells. At subinhibitory concentrations, the macrolide clarithromycin inhibits the expression of adhesins on bacterial cell surfaces. The addition of 5 and 10 microg/ml of Met I to 1/8, 1/16 and 1/32 MIC of clarithromycin potentiated the inhibition of Staphylococcus aureus adhesiveness to human mucosal cells in comparison with the antibiotic alone. This finding opens up a new possibility of interfering with bacterial adhesiveness and its resulting pathogenicity not only by using antibiotics but also by means of their combination with agents devoid of antibacterial activity. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11306790     DOI: 10.1159/000063223

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  5 in total

Review 1.  Erdosteine: antitussive and anti-inflammatory effects.

Authors:  Roberto W Dal Negro
Journal:  Lung       Date:  2008-01-10       Impact factor: 2.584

Review 2.  Reactive Sulfur Compounds in the Fight against COVID-19.

Authors:  Małgorzata Iciek; Anna Bilska-Wilkosz; Michał Kozdrowicki; Magdalena Górny
Journal:  Antioxidants (Basel)       Date:  2022-05-26

3.  Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study.

Authors:  Roberto W Dal Negro; Jadwiga A Wedzicha; Martin Iversen; Giovanni Fontana; Clive Page; Arrigo F Cicero; Edoardo Pozzi; Peter M A Calverley
Journal:  Eur Respir J       Date:  2017-10-12       Impact factor: 16.671

Review 4.  Multifaceted Beneficial Effects of Erdosteine: More than a Mucolytic Agent.

Authors:  Mario Cazzola; Clive Page; Paola Rogliani; Luigino Calzetta; Maria Gabriella Matera
Journal:  Drugs       Date:  2020-11       Impact factor: 9.546

5.  Understanding the Role of the Antioxidant Drug Erdosteine and Its Active Metabolite on Staphylococcus aureus Methicillin Resistant Biofilm Formation.

Authors:  Cristina Cattò; Federica Villa; Francesca Cappitelli
Journal:  Antioxidants (Basel)       Date:  2021-11-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.